

1 **Title:** COVID-19 vaccine effectiveness during a prison outbreak when the Omicron was the
2 dominant circulating variant— Zambia, December 2021

3

4 **Authors:** John Simwanza^{1,2}; Jonas Z. Hines³; Danny Sinyange^{1,2}; Nyambe Sinyange⁴;
5 Chilufya Mulenga^{1,4}; Sarah Hanyinza⁴; Patrick Sakubita⁴, Nelia Langa⁴; Haggai Nowa⁵;
6 Priscilla Gardner⁶; Ngonda Saasa⁷; Gabriel Chipeta⁶; James Simpungwe³; Warren
7 Malambo³; Busiku Hamainza²; Nathan Kapata⁴; Muzala Kapina⁴; Kunda Musonda⁴;
8 Mazyanga Liwewe⁴; Consity Mwale⁶; Sombo Fwoloshi⁹; Lloyd B. Mulenga⁹; Simon Agolory³;
9 Victor Mukonka⁴; Roma Chilengi^{4,10};

10

11 **Affiliations:**

12 ¹Zambia Field Epidemiology Training Programme, Lusaka, Zambia

13 ²National Malaria Elimination Centre, Lusaka, Zambia

14 ³Centers for Disease Control and Prevention, Lusaka, Zambia

15 ⁴Zambia National Public Health Institute, Lusaka, Zambia

16 ⁵Zambia Prison Services, Lusaka, Zambia

17 ⁶Lusaka District Health Office, Lusaka, Zambia

18 ⁷University of Zambia Veterinary Medicine Laboratory School, Lusaka, Zambia

19 ⁸Lusaka Province Health Office, Lusaka, Zambia

20 ⁹Ministry of Health, Lusaka, Zambia

21 ¹⁰Republic of Zambia State House, Lusaka, Zambia

22

23 **Keywords:** COVID-19 vaccines, vaccine efficacy; SARS-CoV-2 variants, prisons, prisoners,
24 Zambia, Africa

25

26 *Abstract:* During a COVID-19 outbreak in a prison in Zambia from 14th to 19th December
27 2021, a case control study was done to measure vaccine effectiveness (VE) against
28 infection and symptomatic infection, when the Omicron variant was the dominant circulating
29 variant. Among 382 participants, 74.1% were fully vaccinated and the median time since full
30 vaccination was 54 days. There were no hospitalizations or deaths. COVID-19 VE against
31 any SARS-CoV-2 infection was 64.8% and VE against symptomatic SARS-CoV-2 infection
32 was 72.9%. COVID-19 vaccination helped protect incarcerated persons against SARS-CoV-
33 2 infection during an outbreak while Omicron was the dominant variant in Zambia.

34

35

36

37

38 *Introduction*

39 COVID-19 continues to ravage the globe as new SARS-CoV-2 variants emerge and cause
40 new waves of infections. The highly transmissible Omicron variant emerged in late 2021,
41 rapidly spreading to many countries and leading to record-breaking case counts globally. In
42 early December 2021, Zambia recorded a rapid rise in confirmed COVID-19 cases,
43 coinciding with confirmation of the Omicron variant in the country. Zambia recorded a daily
44 average of 1,422 confirmed COVID-19 cases in December 2021, compared to an average
45 15 cases daily the previous month, in November 2021. From December 4th to 24th, 2021, all
46 sequenced specimens in Zambia were of the Omicron variant (1).

47 Congregate living settings, including prisons, are at high risk for COVID-19 outbreaks (2).
48 Congested living conditions make physical distancing and avoidance of crowds challenging
49 in many prison settings. Although difficult to enforce, use of face masks in high SARS-CoV-2
50 transmission risk settings can limit the rapid spread of infection (3).

51 On December 14th, 2021, after not recording any COVID-19 cases for months, a local prison
52 in Lusaka noted an increase in the number of residents with respiratory symptoms, 19 of
53 whom tested positive for COVID-19 with rapid diagnostic tests (RDTs). The prison notified
54 the Lusaka District Health Office on the same day and an outbreak investigation was
55 initiated. Mitigation measures were reinforced, including mask distribution and mandatory
56 masking, cohorting persons testing positive and provision of hand hygiene stations
57 throughout the prison. Of 767 persons incarcerated at the facility during the outbreak, 241
58 (31.4%) tested positive for COVID-19 from December 14th to 19th, 2021.

59 COVID-19 vaccines have shown remarkable effectiveness, particularly for reducing COVID-
60 19 severity (4). COVID-19 vaccine effectiveness (VE) against the Omicron variant is lower
61 than against other variants (5,6), although data from the African continent are limited (7–9).
62 Correctional services in Zambia achieved high COVID-19 vaccine coverage among
63 incarcerated persons prior to the Omicron variant wave through onsite vaccination clinics

64 and enhanced COVID-19 screening and testing with encouragement of vaccination for those
65 testing negative. Of the incarcerated persons at this local prison, 619 (80.7%) were
66 vaccinated when the outbreak occurred (compared to 12.6% of the eligible general
67 population in Zambia at the time). We measured VE among incarcerated persons during
68 this outbreak in Zambia.

69

70 *Methods*

71 A case-control study of SARS-CoV-2 infection and symptomatic infection by vaccination
72 status was conducted among persons incarcerated at the prison facility during the outbreak
73 from 15th to 20th December 2021. The facility is in Lusaka, the national capital of Zambia,
74 and houses men aged ≥ 13 years awaiting court cases or transfer to other prisons after
75 sentencing. The prison has five cells built to house 92 persons, although at the outbreak
76 onset 767 persons were incarcerated (i.e., > 800% beyond capacity).

77 During the outbreak, all incarcerated persons were tested for COVID-19 using Panbio
78 COVID-19 Ag rapid test (Abbott Rapid Diagnostics Jena GmbH, Germany) from December
79 14th to 19th, 2021. Cases and controls were incarcerated persons testing COVID-19 positive
80 and negative, respectively. Participants were recruited into the study between December
81 20th to 24th, 2021 by reviewing the outbreak line list maintained by the prison health team
82 and district health office, attempting to frequency match controls by cases' cell assignment.

83 Verbal consent was obtained from the participants and for minors aged 13–17 years.

84 Consent was obtained from the prison warden as per Zambia Correctional Services policy.

85 This study was approved by the ERES Ethics review board and National Health Research
86 Authority. The activity was reviewed by US Centers for Disease Control and Prevention and
87 was conducted consistent with applicable Federal law and CDC policy.

88 A standardized questionnaire that included information on demographics and medical

89 history, including COVID-19 vaccination and test results was administered by trained

90 interviewers. Self-reported COVID-19 test results were confirmed with the line list where the
91 RDT results were recorded. Vaccination status was cross-referenced with the national
92 registry.

93 Full vaccination was defined as having received the 1st dose of a one-dose vaccine or 2nd
94 dose of a two-dose vaccine ≥ 14 days before COVID-19 testing. Partial vaccination was
95 defined as having received the 1st dose of a two-dose vaccine ≥ 14 days before COVID-19
96 testing but not the 2nd dose yet or receiving the 2nd dose ≤ 13 days before testing. Persons
97 who were partially vaccinated or indeterminate status (i.e., received their 1st dose of the One
98 dose vaccine 0-13 days before testing, or had an unknown type of COVID-19 vaccine) were
99 excluded from analyses. Multivariable logistic regression was used to calculate the odds of
100 SARS-CoV-2 infection and symptomatic infection, adjusting for age, number of
101 comorbidities, jail cell, and self-reported mask use. VE was calculated as 1 minus the
102 adjusted odds ratio times 100. To reduce the risk of misclassification bias related to false
103 negative RDT test results, we conducted a sensitivity analysis excluding symptomatic
104 controls.

105

106 *Results*

107 In total, 385 (50.2%) of the 767 incarcerated persons present during the outbreak were
108 reached for interview and 382 (49.8%) consented to being enrolled in the study. All were
109 males, with a median age of 28 years (interquartile range [IQR]: 21-36 years) (Table 1).
110 Overall, 84 (22.0%) had at least one comorbidity, with HIV being most common (n = 40,
111 10.5%). Only 16 (4.1%) reported having had COVID-19 previously.

112 Overall, 294 (77.0%) participants received ≥ 1 COVID-19 vaccine dose; of these 283 (96.3%)
113 were fully vaccinated, 1 (0.3%) partially vaccinated and 10 (3.4%) indeterminate. Among
114 fully vaccinated participants, 253 (89.4%) received the one-dose Janssen vaccine and 30
115 (10.6%) received the two-dose AstraZeneca vaccines. None had received an additional

116 ('booster') vaccine dose. The median time since receipt of a full primary vaccine series was
117 54 days (IQR: 28-85 days).

118 There were 180 (47.1%) COVID-19 positive incarcerated persons (i.e., cases) and 202
119 (52.9%) COVID-19 negative persons (i.e., controls). Among positive cases, 117 (65.0%)
120 were in fully vaccinated persons (i.e., breakthrough infections). Of the 16 (4.1%) persons
121 reporting prior confirmed COVID-19, 5 (29.4%) were positive during the outbreak (i.e.,
122 reinfections).

123 Overall, 104 (27.2%) persons reported any COVID-19 symptoms, with a greater proportion
124 among cases (45.6% vs. 10.9%; $p < 0.01$, chi-square test). The most common symptoms
125 among COVID-19 cases were cough (37.8%), rhinorrhoea (20.6%), headache (17.2%), and
126 myalgias (12.8%) (Table 1). Eighty-nine (49.4%) of the 180 participants with cases sought
127 medical care at the prison clinic, and none (0%) were admitted or died. Cases were more
128 likely to have sought health care. There were no differences among the cases and controls
129 in terms of age, number of comorbidities, prior Covid-19, or mask use.

130 Cases were less likely to be fully vaccinated than controls (66.9% versus 84.7%; $p < 0.01$,
131 chi-square test) (Table 2). VE against SARS-CoV-2 infection was 64.8% (95% confidence
132 interval [CI]: 36.1-81.0%) and VE against symptomatic SARS-CoV2 infection was 72.9%
133 (95% CI: 42.0-87.5%). The median time to vaccination was less than two months and the VE
134 was higher for those vaccinated within the past 60 days compared to >60 days before
135 COVID-19 testing, although the confidence intervals overlapped (VE for SARS-CoV-2
136 infection: 74.6% [95% CI: 50.3-87.4%] vs. 54.2% [95% CI: 6.9-77.9%], respectively). VE of
137 Janssen vaccine against SARS-CoV-2 infection was 63.6% (95% CI: 33.6-80.5%) and
138 against symptomatic infection was 73.0% (95% CI: 41.6-87.7%). VE of AstraZeneca against
139 SARS-CoV-2 infection was 89.4% (95% CI: 59.5-97.8%) and against symptomatic infection
140 was 83.7% (95% CI: 60.8-93.6%). The sensitivity analysis excluding symptomatic controls
141 did not meaningfully change the VE estimates (VE against SARS-CoV-2 infection was

142 64.1% [95% CI: 35.8-80.2%] and VE against symptomatic SARS-CoV2 infection was 73.4%
143 [95% CI: 44.6-87.4%]). Forty persons (10.5%) in the analysis reported being HIV positive,
144 among who 83.3% of unvaccinated PLHIV tested SARS-CoV-2 positive compared to 50.0%
145 of fully vaccinated PLHIV ($p = 0.20$, chi-square test). Among PLHIV, VE against SARS-CoV-
146 2 infection was 82.2% (95% CI: -107-99.4%).

147

148 *Discussion*

149 During a prison COVID-19 outbreak in Zambia, COVID-19 vaccination protected against
150 SARS-CoV-2 infection and symptomatic illness while Omicron was the dominant strain in the
151 country (1). These findings provide important evidence that might help increase COVID-19
152 vaccination in Zambia, where many more Zambians need to be vaccinated to reach the
153 African Union targets adopted by the country (10).

154 The SARS-CoV-2 Omicron variant contains numerous mutations to the spike protein which
155 may lead to immune evasion. VE estimates reported here are lower compared to prior
156 strains (11,12), and the high proportion of breakthrough infections in this outbreak supports
157 in theory the possibility of immune evading capability of Omicron. In this study, VE was
158 higher for symptomatic illness than any infection; VE for severe illness could not be
159 accessed because no persons were hospitalized or died during this outbreak although other
160 studies have demonstrated durability against this important outcome (13). Similarly, VE of a
161 booster dose could not be assessed because Zambia did not begin offering a booster dose
162 until January 2022. The relatively short time since vaccination might explain the relatively
163 higher effectiveness findings against Omicron (6,14,15), although there was a suggestion of
164 waning immunity when comparing the VE point estimates of participants fully vaccinated
165 over two months before the outbreak with those vaccinated within the past two months. Our
166 findings are encouraging considering alarm raised early in the Omicron wave about the

167 vaccines widely available in Africa being ineffective against reducing SARS-CoV-2
168 transmission (16).

169 Notably, symptomology was mild among participants, which is consistent with reports from
170 other countries that are experiencing Omicron surges (9,17). Animal evidence suggests this
171 might be related to tropism of Omicron for upper respiratory epithelium relative to the lower
172 respiratory tract (18). This finding might also reflect the relatively younger age of persons in
173 this outbreak. The role of pre-existing immunity in Zambia from natural infection remains
174 uncertain and serosurveys would be useful to understand to what proportion of people in
175 Zambia have been infected with SARS-CoV-2.

176 This study had several limitations. All cases were confirmed with RDTs, which have lower
177 sensitivity than PCR tests (19). Additionally, beyond initial test results, serial testing was not
178 available meaning some controls might have been in their incubation period at the time of
179 testing and therefore misclassified. Omicron was not confirmed by genomic sequencing in
180 this outbreak, so the outbreak could have been from another strain; however, Omicron was
181 already dominant in Zambia before this outbreak occurred (20). Lastly, although few
182 participants reported a prior confirmed SARS-CoV-2 infection, the actual number might be
183 much higher considering only a small proportion of cases are confirmed in Zambia (21).

184 Rapid investigation of an outbreak in a closed setting demonstrated VE of COVID-19
185 vaccines against Omicron infection in Zambia. COVID-19 vaccination remains a critical tool
186 in decreasing SARS-CoV-2 transmission and severity especially when coupled with a
187 layered prevention including well-fitting facemask use, hand hygiene, limiting large
188 gatherings, and adequate ventilation and/or outdoor gatherings. Continuing to rapidly scale
189 COVID-19 vaccination to all eligible persons in Zambia can help prevent SARS-CoV-2
190 transmission and symptomatic COVID-19.

191

192

193

194 *Attribution of Support.* This work has been supported by the President's Emergency Plan for
195 AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) and
196 the CDC Emergency Response to the COVID-19 pandemic.

197

198 *Disclaimer.* The findings and conclusions in this report are those of the author(s) and do not
199 necessarily represent the official position of the funding agencies. Use of trade names is for
200 identification only and does not imply endorsement by the funding agencies.

201

202 *References*

- 203 1. GISAID - EpiCov [Internet]. [cited 2022 Feb 18]. Available from:
204 <https://www.epicov.org/epi3/frontend#220b8c>
- 205 2. Hagan LM, McCormick DW, Lee C, Sleweon S, Nicolae L, Dixon T, et al. Outbreak of
206 SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a
207 Federal Prison — Texas, July–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021
208 Sep;70(38):1349–54.
- 209 3. Centers for Disease Control and Prevention (CDC). Science Brief: Community Use of
210 Masks to Control the Spread of SARS-CoV-2 [Internet]. December 6, 2021. [cited
211 2022 Mar 5]. Available from: [https://www.cdc.gov/coronavirus/2019-
212 ncov/science/science-briefs/masking-science-sars-cov2.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html)
- 213 4. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
214 COVID-19 vaccines: a literature review and meta-analysis. *Int J Infect Dis*. 2022
215 Jan;114:252–60.
- 216 5. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al.
217 Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of
218 concern. *medRxiv* [Internet]. 2021 Dec;2021.12.14.21267615. Available from:
219 [https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1%0Ahttps://www.m
220 edrxiv.org/content/10.1101/2021.12.14.21267615v1.abstract](https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1.abstract)
- 221 6. Thompson MG, Natarajan K, Irving SA. Effectiveness of a Third Dose of mRNA
222 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care
223 Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron
224 Variant Predominance — VISION Network, 10 States, August 2021–. *Morb Mortal
225 Wkly Rep* [Internet]. ePub: 21 J. Available from:
226 [https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#sugg
227 estedcitation](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcitation)

- 228 7. Grey GE, Collie S, Garrett N, Goga A, Champion J, Zylstra M, et al. Vaccine
229 effectiveness against hospital admission in South African health care workers who
230 received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave:
231 Preliminary Results of the Sisonke 2 Study. medRxiv [Internet]. Available from:
232 <https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1>
- 233 8. Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al.
234 Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa
235 (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation
236 study. *Lancet* (London, England). 2022 Mar;399(10330):1141–53.
- 237 9. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2
238 Vaccine against Omicron Variant in South Africa. Vol. 386, *The New England journal*
239 *of medicine*. 2022. p. 494–6.
- 240 10. World Health Organization (WHO). Leaders Make Urgent Call To Accelerate
241 Vaccination Globally And In Africa [Internet]. Geneva, Switzerland; Available from:
242 [https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-](https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-vaccination-globally-and-in-africa)
243 [vaccination-globally-and-in-africa](https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-vaccination-globally-and-in-africa)
- 244 11. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al.
245 Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson &
246 Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without
247 Immunocompromising Conditions — United States, March–August 2021. *MMWR*
248 *Morb Mortal Wkly Rep*. 2021 Sep;70(38):1337–43.
- 249 12. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of
250 Covid-19 Vaccines over a 9-Month Period in North Carolina. *N Engl J Med*. 2022 Jan;
- 251 13. Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al.
252 Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive
253 Mechanical Ventilation and Death - United States, March 2021-January 2022. *MMWR*

- 254 Morb Mortal Wkly Rep. 2022 Mar;71(12):459–65.
- 255 14. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19
256 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022
257 Apr;386(16):1532–46.
- 258 15. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning
259 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated
260 Emergency Department and Urgent Care Encounters and Hospitalizations Among
261 Adults During Periods of Delta and Omicron Variant Predominance - VISION Network,
262 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022
263 Feb;71(7):255–63.
- 264 16. Nolen S. Most of the World’s Vaccines Likely Won’t Prevent Infection From Omicron.
265 The New York Times [Internet]. Available from:
266 <https://www.nytimes.com/2021/12/19/health/omicron-vaccines-efficacy.html>
- 267 17. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics
268 and Outcomes of Hospitalized Patients in South Africa During the COVID-19
269 Omicron Wave Compared With Previous Waves. JAMA. 2021 Dec;
- 270 18. Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, et al. SARS-CoV-2
271 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta
272 variants strains in a mouse model of severe COVID-19. bioRxiv. 2021
273 Dec;2021.12.26.474085.
- 274 19. Akingba OL, Sprong K, Marais G, Hardie DR. Field performance evaluation of the
275 PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant
276 in the Eastern Cape, South Africa. J Clin Virol Plus [Internet]. 2021;1(1–2):100013.
277 Available from: <https://doi.org/10.1016/j.jcvp.2021.100013>
- 278 20. Mwenda-Chimfwembe M, Saasa N, Bridges D. Genomic epidemiology of novel

279 coronavirus - Africa_Zambia-focused subsampling [Internet]. [cited 2022 Feb 16].
280 Available from: <https://nextstrain.org/groups/SC2ZamPub/ncov/africa/zambia>

281 21. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence
282 of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster
283 sample survey. *Lancet Glob Heal.* 2021;(21):1–9.

284

285

286 Table 1. Characteristics and outcomes of cases and controls during an COVID-19 outbreak
 287 in a prison in Zambia, December 2021

Variable	Cases* (N=180)	Controls* (N=202)	p-value [†]
Age, median years (IQR)	27 (21-36)	28 (21-36)	0.58
Imprisonment duration, median days (IQR)	41 (13-96)	43 (17-120)	0.79
Education level, n (%)			
None	5 (2.8)	5 (2.5)	0.34
Primary	68 (37.8)	63 (31.2)	
Secondary	82 (45.6)	111 (55)	
Tertiary	25 (13.9)	23 (11.4)	
Nationality, n (%)			
Zambian	143 (79.4)	176 (87.1)	0.06
Other	37 (20.6)	26 (12.9)	
Any comorbidity, n (%) [‡]	38 (21.1)	46 (22.8)	0.79
Comorbidity type, n (%)			
HIV	22 (12.2)	18 (8.9)	0.38
Hypertension	9 (5.0)	5 (2.5)	0.30
Cardiac disease	2 (1.1)	4 (2.0)	0.79
Diabetes	1 (0.6)	5 (2.5)	1.00
Renal disease	2 (1.1)	2 (1.0)	0.92
Pulmonary disease	1 (0.6)	1 (0.5)	1.00
Tuberculosis	1 (0.6)	2 (1.0)	1.00
Liver disease	1 (0.6)	1 (0.5)	1.00
Other	6 (3.4)	14 (7.1)	0.18
Prior COVID-19, n (%)	5 (2.8)	11 (5.4)	0.13
Mask use			
Always or most of the time	97 (53.9)	106 (52.5)	0.14
Sometimes or rarely	51 (28.3)	72 (35.6)	
Don't use a mask	32 (17.8)	24 (11.9)	
Timing of 1st Vaccine Dose, n (%)			
≥14 days before testing	118 (65.0)	168 (83.2)	<0.01
0-13 days before testing [¶]	4 (2.2)	4 (2.0)	
After testing	0 (0.0)	0 (0.0)	
Not vaccinated	58 (32.2)	30 (14.9)	
Vaccine type (n = 294), n (%)			
Janssen (J&J)	110 (90.2)	151 (87.8)	0.75
AstraZeneca	11 (9.0)	20 (11.6)	
Not known	1 (0.8)	1 (0.6)	
Vaccination status, n (%) ^{**}			
Fully	117 (65.0)	166 (82.2)	<0.01
Partially	0 (0.0)	1 (0.5)	
Indeterminate	5 (2.8)	5 (2.5)	
Unvaccinated	58 (32.2)	30 (14.9)	

Time since vaccination, median days (IQR)	56 (33-91)	53 (27-84)	0.02
Symptomatic, n (%)	82 (45.6)	22 (10.9)	<0.01
Symptoms, n (%)			
Cough	68 (37.8)	18 (8.9)	1.00
Rhinorrhea	37 (20.6)	6 (3.0)	0.21
Headache	31 (20.6)	6 (3.0)	0.51
Myalgia	23 (12.8)	2 (1.0)	0.12
Fever	18 (10.0)	3 (1.5)	0.57
Fatigue	10 (5.6)	1 (0.5)	0.52
Sore throat	9 (5.0)	6 (3.0)	1.00
Chills	6 (3.3)	2 (1.0)	1.00
Sinus congestion	3 (1.7)	1 (0.5)	NC
Loss of taste	2 (1.1)	0 (0.0)	NC
Loss of smell	2 (1.1)	0 (0.0)	NC
Others	5 (2.8)	2 (1.0)	NC
Sought health care, n (%)	89 (49.4)	17 (8.4)	<0.01
Admitted to hospital, n (%)	0 (0.0)	0 (0.0)	NC
Died, n (%)	0 (0.0)	0 (0.0)	NC

* Cases were participants with a positive SARS-CoV-2 rapid diagnostic test (RDT) results and controls were participants with a negative RDT result

† Student's t-test for continuous variables and chi-square test or Fischer exact test (where any cell size <10) for categorical variables

‡ Comorbidities included: hypertension, cardiac disease, obesity, pulmonary disease, kidney disease, liver disease, diabetes, cancer, HIV, and tuberculosis (current or past)

¶ Participants classified as indeterminate because immune status at time of testing was unknown

** Partial vaccination was defined as having received the 1st dose of a two-dose vaccine ≥14 days before COVID-19 testing but not the second dose or the 2nd dose ≤13 days before testing. Full vaccination was defined as having received the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days before COVID-19 testing. Persons who were vaccinated with their 1st dose 0-13 days before testing were considered to have indeterminate vaccination status and excluded from analyses.

IQR: interquartile range; NC: not calculated

288

289

290 Table 2. COVID-19 vaccine effectiveness against Omicron variant – Zambia, December 2021

Vaccination status	Fully vaccinated, n (%)		Vaccine effectiveness, % (95% CI)*	
	Cases	Controls	SARS-CoV-2 infection	Symptomatic infection
Vaccine brand [†]				
Any vaccine (n = 371)	117 (66.9)	166 (84.7)	64.8 (36.1-81.0)	72.9 (42.0-87.5)
Janssen (n = 341)	106 (64.6)	147 (83.1)	63.6 (33.6-80.5)	73.0 (41.6-87.7)
AstraZeneca (n = 118)	11 (15.9)	19 (38.8)	89.4 (59.5-97.8)	85.1 (19.5-98.0)
Vaccination timing [†]				
≤60 days (n = 249)	59 (50.4)	102 (77.3)	74.6 (50.3-87.4)	83.7 (60.8-93.6)
>60 days (n = 210)	58 (50.0)	64 (68.1)	54.2 (6.9-77.9)	53.2 (-16.6-81.6)

* Adjusted for age, number of comorbidities, jail cell, and mask use

[†] Analysis presented for fully vaccinated persons only. One person was partially vaccinated and 10 were indeterminate vaccination status (i.e., vaccinated with their 1st dose 0-13 days before COVID-19 testing)

CI: confidence interval

